Opendata, web and dolomites

ONCOTECT SIGNED

Early detection of tumor DNA in liquid biopsies as a biomarker of cancer recurrence

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 ONCOTECT project word cloud

Explore the words cloud of the ONCOTECT project. It provides you a very rough idea of what is the project "ONCOTECT" about.

sensitive    superior    assay    blood    integration    start    freedom    competing    considerable    cohort    workflow    types    remission    operate    ambition    carry    diagnostic    leveraging    standard    regulatory    fto    dna    reliably    methodology    underlying    mutations    proof    detect    breaking    tumor    cyclomics    oncogenic    90    lesions    hnc    unable    sme    vision    circulating    encompassing    patients    ground    tp53    first    death    head    examination    ct    company    sequencing    recurrent    commercialization    detects    monitoring    market    delays    biopsies    detection    spectrum    initial    liquid    rates    survival    feasibility    disease    obtain    detecting    genes    gene    kit    accurate    decision    screening    programs    care    samples    dutch    full    fast    time    bv    diagnostics    strategy    licensing    treatment    critical    ultra    cancer    opportunity    radiological    proprietary    quality    inexpensive    neck    lower    disrupt    clinical    recurrence    relative    oncotect    ivd    vitro    routine    faster   

Project "ONCOTECT" data sheet

The following table provides information about the project.

Coordinator
CYCLOMICS BV 

Organization address
address: MOSKEEPLEIN 82
city: UTRECHT
postcode: 3531 BX
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Netherlands [NL]
 Project website https://www.cyclomics.com/technology.html
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-06-01   to  2019-11-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    CYCLOMICS BV NL (UTRECHT) coordinator 50˙000.00

Map

 Project objective

Cyclomics BV is a Dutch start-up company with the ambition to disrupt the cancer diagnostics market with its proprietary circulating tumor (ct) DNA detection technology. Cyclomics has developed a ground-breaking sequencing methodology that enables reliable, fast and ultra-sensitive detection of cancer recurrence from blood samples (liquid biopsies). The first product, ONCOTECT, detects oncogenic mutations in the TP53 gene, and is developed for accurate and early detection of head and neck cancer (HNC) recurrence. Recurrent disease after initial remission is a main cause of cancer-related death. In HNC, radiological examination is the current standard in detecting cancer lesions but is unable to reliably detect recurrence early on, leading to treatment delays and lower survival rates. Integration of the ONCOTECT assay into routine clinical workflow is inexpensive and will provide faster time-to-results relative to competing sequencing methods. Since 90% of HNC patients carry specific oncogenic DNA mutations in the TP53 gene, the first application of this novel technology in recurrent HNC presents a considerable market opportunity for ONCOTECT. After achieving clinical proof-of-concept in a cohort of 20 patients, Cyclomics will offer its technology for licensing to a diagnostics company to further develop ONCOTECT as an in vitro diagnostic (IVD) kit and bring it to the market, with the aim of enabling superior quality in diagnostic and clinical decision making. ONCOTECT focuses on TP53 but the underlying technology can be applied to many different genes. Leveraging this potential, Cyclomics’ long-term vision includes monitoring of cancer treatment response and early screening programs, encompassing various genes and cancer types, with the potential to impact the full spectrum of cancer care. In this SME feasibility study, Cyclomics will obtain critical insight for commercialization strategy, including freedom to operate (FTO), user needs and regulatory requirements.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ONCOTECT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "ONCOTECT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

PrasinoMed (2018)

First in the world ecological and sustainable cream for wound care, based on microalgaprasinococcus capsulatus

Read More  

GREEN WHS (2019)

NATURE FRIENDLY WATER HYDRAULIC STEERING SYSTEM

Read More  

SmartDegrees (2020)

First anti-fraud plataform for the registration and certification of diplomas and academic certificates based in blockchain

Read More